StockDrifts LogoStockDrifts

remed 302550

Company
리메드remed
Insiders
4
Buys
10
Total Value
₩27M ($19K)
Avg Return
+10.21%
Last Filing
2026-04-09

remed (302550) has 10 disclosed insider purchases and 0 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩27M ($19K) in reported transaction value. The earliest filing StockDrifts holds for remed is dated 2026-01-27; the most recent is 2026-04-09. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +10.21%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-04-09BUYMarket Buy
김태군
Taegun Kim
Executive Officer (CTO)3.3K₩2,910+9.3%₩10M ($7K)
2026-02-25BUYMarket Buy
신대현
Daehyun Shin
Executive Officer (CPO)2.5K---
2026-02-05BUYMarket Buy
송종은
Song Jong-eun
Executive Officer (CSO)300₩2,800+12.5%₩840K ($583)
2026-02-05BUYMarket Buy
송종은
Song Jong-eun
Executive Officer (CSO)1.0K₩2,800+12.5%₩3M ($2K)
2026-02-03BUYMarket Buy
송종은
Song Jong-eun
Executive Officer (CSO)600₩2,810+12.1%₩2M ($1K)
2026-02-02BUYMarket Buy
송종은
Song Jong-eun
Executive Officer (CSO)600₩2,760+14.1%₩2M ($1K)
2026-01-30BUYMarket Buy
송종은
Song Jong-eun
Executive Officer (CSO)600₩2,860+10.1%₩2M ($1K)
2026-01-28BUYMarket Buy
신대현
Daehyun Shin
Executive Officer (CPO)100₩2,955+6.6%₩296K ($205)
2026-01-27BUYMarket Buy
이정수
Jeongsoo Lee
Executive Officer (CFO)3.0K₩2,935+7.3%₩9M ($6K)
2026-01-27BUYMarket Buy
이정수
Jeongsoo Lee
Executive Officer (CFO)45₩2,935+7.3%₩132K ($92)

Frequently asked questions

Who has been buying remed stock?
4 distinct insiders have filed 10 disclosed insider purchases in remed (302550), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does remed have?
remed has 10 buy-side and 0 sell-side disclosures on record, covering ₩27M ($19K) in total reported value, spanning 2026-01-27 to 2026-04-09.
Where does StockDrifts get remed insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for remed. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.